摘要
回顾过去30年,虽经历了免疫预防和抗病毒治疗,但慢性乙型肝炎(chronic hepatitis B,CHB)仍然是全球严重的公共卫生问题。预防和减少CHB进展为终末期肝病成为当务之急。目前,最有效的方法是早期抗乙型肝炎病毒(hepatitis B virus,HBV)治疗,这也是近年各大权威机构颁布的指南扩大抗HBV治疗适应证的重要目标之一。本文从核苷(酸)类似物[nucleos(t)ide analogues,NAs]的疗效与局限、干扰素(interferon,IFN)在实现临床治愈中的作用与困局、抗HBV新药的现状与前景以及抗HBV新策略展望这几方面进行述评。
Over the past three decades,despite advancements in immunization and antiviral therapies,chronic hepatitis B(CHB)has remained a major global public health challenge.The urgent priority now lies in preventing and reducing the progression of CHB to end-stage liver disease.At present,the most effective approach is the early initiation of anti-hepatitis B virus(HBV)therapy,which has also become a critical objective in recent guidelines issued by major authoritative bodies to expand the indications for anti-HBV treatment.This article provides a comprehensive review of several key aspects,including the efficacy and limitations of nucleos(t)ide analogs(NAs),the role and challenges of interferon(IFN)in achieving clinical cure,the current status and future prospects of novel anti-HBV drugs,and the outlook for emerging anti-HBV strategies.
作者
刘慧敏
毛青
Liu Huimin;Mao Qing(Department of Infectious Diseases,Southwest Hospital,Third Military Medical University(Army Medical University),Chongqing Key Laboratory of Precision Prevention and Control of Viral Infectious Diseases,Chongqing 400038,China)
出处
《中华实验和临床病毒学杂志》
2025年第4期393-396,共4页
Chinese Journal of Experimental and Clinical Virology
关键词
乙型肝炎病毒
慢性感染
抗病毒治疗
新药研发
Hepatitis B virus
Chronic infection
Antiviral therapy
New drug development
作者简介
通信作者:毛青,Email:qingmao@tmmu.edu.cn,电话:023-68765611。
